Volume 43, number S4: Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir
16th Nov 2006, 21:43 GMT
We examined drug interactions between buprenorphine, an opioid partial agonist available by prescription for treatment of opioid dependence, and the protease inhibitors (PIs) nelfinavir (NFV), ritonavir (RTV), and lopinavir/ritonavir (LPV/R). Opioid-dependent, buprenorphine/naloxone-maintained, human immunodeficiency virus (HIV)–negative volunteers ([FORMULA] per PI) participated in 24-h pharmacokinetic studies, before and after administration of each PI. Symptoms of opiate withdrawal and excess were determined before and after PI administration. PI pharmacokinetics were determined and compared between opiate-dependent participants and healthy control participants ([FORMULA] per PI). Administration of RTV, but not of NFV or LPV/R, resulted in a significant increase in the buprenorphine area under the concentration-time curve (AUC). Symptoms of opiate excess, however, were not observed. Buprenorphine had no significant effects on PI AUC. Adjustments of doses of either buprenorphine or NFV, LPV/R, or RTV are not likely to be necessary when these drugs are administered for the treatment of opioid dependence and HIV disease.
Latest news from Clin Infect Dis Latest Issue:
- Volume 43, number S4: Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment
- Volume 43, number S4: Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments
- Volume 43, number S4: The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention
- Volume 43, number S4: A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
- Volume 43, number S4: Initial Strategies for Integrating Buprenorphine into HIV Care Settings in the United States
- Volume 43, number S4: Buprenorphine Use: The International Experience
- Volume 43, number S4: Pharmacokinetic Interactions between Buprenorphine and Antiretroviral Medications
- Volume 43, number S4: Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine
- Volume 43, number S4: Overcoming Policy and Financing Barriers to Integrated Buprenorphine and HIV Primary Care
- Volume 43, number S4: Buprenorphine and HIV Primary Care: Report of a Forum for Collaborative HIV Research Workshop